Objective
Tuberculosis is still a serious health problem especially in developing countries, where the incidence is increasing. Tanzania, which is the third World partner in this project observed a doubling of new TB cases in 1990 compared With 1983. This increase has been ascribed to the AIDS epidemic. Mány aspects of the relationship between TB and HIV infection are not fully understood.
The proposed project aims at characterizing mycobacteria from HIV positive and HIV negative patients in terms of species - , strain distribution, and drug sensitivities.
By applying methods Which are considered conventional in developed countries but which are not being used to any greater extent in the third world it may be possible to get a new picture of the species distribution and drug sensitivity pattern from a high endemic area.
By applying the Restriction Fragment Length polymorphism (RFLP) analysis on the M.tuberculosis isolates it may be possible to follow strain pattern s and compare isolates from HIV positive and HIV negative patients. These data may add information to our understanding of the role of reactivation versus infection.
It has been proposed that the BCG vaccine may get reactivated in patients immunosuppressed by HIV. This study may also adress this aspect. The training component is an important aspect of this proposal as staff from the Tanzanian laboratory will receive training at the KIT and at SSI. An ELISA based method for the identification of various mycobacterial Species will be evaluated. The method should be easily transferable to modestly equipped laboratories.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine allergology drug allergy
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences clinical medicine pneumology tuberculosis
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
2300 KOEPENHAGEN
Denmark
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.